DK2608806T3 - Epstein-barr-virusvaccine - Google Patents

Epstein-barr-virusvaccine

Info

Publication number
DK2608806T3
DK2608806T3 DK11751867.0T DK11751867T DK2608806T3 DK 2608806 T3 DK2608806 T3 DK 2608806T3 DK 11751867 T DK11751867 T DK 11751867T DK 2608806 T3 DK2608806 T3 DK 2608806T3
Authority
DK
Denmark
Prior art keywords
particle
ebv
vaccine
epstein
barr virus
Prior art date
Application number
DK11751867.0T
Other languages
English (en)
Inventor
Romana Ruiss
Gilbert Reisbach
Wolfgang Hammerschmidt
Reinhard Zeidler
Original Assignee
Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH)
Univ Muenchen Ludwig Maximilians
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH), Univ Muenchen Ludwig Maximilians filed Critical Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH)
Application granted granted Critical
Publication of DK2608806T3 publication Critical patent/DK2608806T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16211—Lymphocryptovirus, e.g. human herpesvirus 4, Epstein-Barr Virus
    • C12N2710/16223—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16211—Lymphocryptovirus, e.g. human herpesvirus 4, Epstein-Barr Virus
    • C12N2710/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16211—Lymphocryptovirus, e.g. human herpesvirus 4, Epstein-Barr Virus
    • C12N2710/16251—Methods of production or purification of viral material
    • C12N2710/16252—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16211—Lymphocryptovirus, e.g. human herpesvirus 4, Epstein-Barr Virus
    • C12N2710/16261—Methods of inactivation or attenuation
    • C12N2710/16262—Methods of inactivation or attenuation by genetic engineering
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16211—Lymphocryptovirus, e.g. human herpesvirus 4, Epstein-Barr Virus
    • C12N2710/16271—Demonstrated in vivo effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DK11751867.0T 2010-08-25 2011-08-25 Epstein-barr-virusvaccine DK2608806T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US37702710P 2010-08-25 2010-08-25
EP10008835 2010-08-25
PCT/EP2011/064672 WO2012025603A1 (en) 2010-08-25 2011-08-25 An epstein-barr-virus vaccine

Publications (1)

Publication Number Publication Date
DK2608806T3 true DK2608806T3 (da) 2018-01-29

Family

ID=43478663

Family Applications (1)

Application Number Title Priority Date Filing Date
DK11751867.0T DK2608806T3 (da) 2010-08-25 2011-08-25 Epstein-barr-virusvaccine

Country Status (7)

Country Link
US (2) US20140227305A1 (da)
EP (1) EP2608806B1 (da)
JP (1) JP2013541507A (da)
CN (1) CN103328003A (da)
DK (1) DK2608806T3 (da)
ES (1) ES2655535T3 (da)
WO (1) WO2012025603A1 (da)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2797626B1 (en) 2011-12-30 2019-07-03 Deutsches Krebsforschungszentrum Second generation virus-like particles (vlp) from epstein-barr viruses for vaccination purposes
DE102012105193B4 (de) * 2012-06-15 2014-04-03 Eberhard-Karls-Universität Tübingen Universitätsklinikum Stimulation der zellulären Immunantwort gegen das Epstein-Barr-Virus (EBV)
CN109893648A (zh) 2013-06-28 2019-06-18 奥克兰联合服务有限公司 氨基酸缀合物和肽缀合物及缀合方法
RU2017126206A (ru) 2014-12-23 2019-01-25 Маргарет Анне БРИМБЛЕ Аминокислотные и пептидные конъюгаты и направления их использования
US10314906B2 (en) 2015-03-18 2019-06-11 University Of Massachusetts Virus-like particle compositions and vaccines against Epstein-Barr virus infection and disease
TW201735952A (zh) 2016-02-26 2017-10-16 瑪格蕾特 安 布萊博 胺基酸及肽共軛物以及共軛過程
EP3423092A1 (en) * 2016-03-01 2019-01-09 Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Means and methods for treating herpesvirus infection
EP3320917A1 (en) * 2016-11-10 2018-05-16 Deutsches Krebsforschungszentrum Improved ebv vaccine
JP2021519598A (ja) 2018-04-03 2021-08-12 サノフイＳａｎｏｆｉ 抗原性エプスタインバーウイルスポリペプチド
JP7500553B2 (ja) * 2018-10-12 2024-06-17 ドイチェス クレブスフォルシュンクスツェントルム 拡大された抗原性スペクトルを有するエプスタイン・バーウイルス様粒子
US20210398689A1 (en) * 2020-06-23 2021-12-23 Corsight.Ai Autonomous mapping and monitoring potential infection events
CN111620955B (zh) * 2020-07-01 2022-11-08 北京康爱瑞浩细胞技术有限公司 一种多靶位复合抗原及其应用
WO2022073234A1 (zh) * 2020-10-10 2022-04-14 中山大学肿瘤防治中心 一种抑制eb病毒的肽和编码该肽的dna及其应用
EP4232076A1 (en) 2020-10-20 2023-08-30 The Chancellor, Masters and Scholars of The University of Oxford Methods and compositions for treating epstein barr virus-associated cancer
EP4232085A1 (en) 2020-10-20 2023-08-30 Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt GmbH Method for manufacturing hek293 cell line, method for manufacturing eb-vlps and composition comprising said eb-vlps
CN114657191B (zh) * 2022-02-18 2023-08-01 中山大学肿瘤防治中心（中山大学附属肿瘤医院、中山大学肿瘤研究所） 一种EBNA3A截短mRNA相关疫苗及其制备方法和应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1948232A4 (en) * 2005-11-18 2010-09-22 Univ Ohio State Res Found VIRAL GENE PRODUCTS AND VACCINATION METHODS FOR PREVENTING ASSOCIATED VIRAL DISEASES
EP2065462A1 (en) * 2007-11-27 2009-06-03 Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Ex vivo method for producing a preparation containing CD4+ T cells specific for EBV structural antigens
JP5683476B2 (ja) * 2008-11-03 2015-03-11 タケダ ヴァクシーンズ， インコーポレイテッド 感染因子を含まないエンベロープウイルスベースｖｌｐを単離するための改良法

Also Published As

Publication number Publication date
US20140227305A1 (en) 2014-08-14
US10300129B2 (en) 2019-05-28
US20160296618A1 (en) 2016-10-13
CN103328003A (zh) 2013-09-25
EP2608806A1 (en) 2013-07-03
ES2655535T3 (es) 2018-02-20
JP2013541507A (ja) 2013-11-14
EP2608806B1 (en) 2017-10-25
WO2012025603A1 (en) 2012-03-01

Similar Documents

Publication Publication Date Title
DK2608806T3 (da) Epstein-barr-virusvaccine
CY1122654T1 (el) Ενωσεις για βελτιωμενη iiκη μεταγωγη
CY1118138T1 (el) Ιοσωματιο απελευθερουμενο μετα απο μολυνση κυτταρων θηλαστικων απο ανθρωπινο κυτταρομεγαλοϊο (hcmv) το οποιο περιεχει μια πρωτεϊνη συντηξης και χρηση αυτου
HRP20181422T1 (hr) Mdck-derivirane stanične linije prilagođene kulturi bez seruma i suspenzijskoj kulturi te postupak proizvodnje virusa cjepiva koristeći navedene stanice
MX2015005505A (es) Vacunas basadas en particular recombinantes contra la infeccion de citomegalovirus humano.
WO2011109833A3 (en) Induced dendritic cell compositions and uses thereof
WO2013142324A8 (en) Neutralizing antibodies to hiv-1 and their use
IL251338B (en) Plant cells and extracts containing virus-like particles containing chimeric viral proteins and compounds thereof
WO2013070776A8 (en) Neutralizing gp41 antibodies and their use
MX2021006342A (es) Mutantes de virus de influenza y usos para los mismos.
WO2011143650A3 (en) Recombinant hcmv and rhcmv vectors and uses thereof
MX2010003713A (es) Vacunas de citomegalovirus y metodos de produccion.
EP3199545A3 (en) Computationally optimized broadly reactive antigens for h1n1 influenza
GB2513768A (en) Complexes of cytomegalovirus proteins
MX359903B (es) Proteínas estructurales de una mutación del parvovirus como vacunas.
PH12015500499A1 (en) Recombinant measles virus expressing chikungunya virus polypeptides and their applications
WO2011137354A3 (en) Delivery proteins
WO2013096866A3 (en) Processes using vlps with capsids resistant to hydrolases
IN2014CN03077A (da)
WO2011057254A3 (en) Simian adenoviral vector-based vaccines
WO2011112601A3 (en) Continuous flow bioreactor for magnetically stabilized three-dimensional tissue culture
WO2012038832A3 (en) Generation of replicating chimeric measles virus - retrovirus particles
HK1162599A1 (en) An infectious recombinant cloning system of duck enteritis virus vaccine strain, construction method and use thereof
WO2015120542A8 (en) Hybrid proteins and uses thereof
EA201270577A1 (ru) Усовершенствованные способы обратной генетики для спасения вирусов